Founded in 2021 and headquartered in New York City. We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principal of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines.
External link for Harmonic Discovery
New York, NY, US
Harmonic Discovery reposted this
I truly appreciated the opportunity to speak at the Biden Cancer Moonshot Workshop: Using AI Approaches to Target Undruggable Cancer Targets in Washington, DC. It was a great event filled with insightful discussions on the latest advancements in AI, structural biology, and systems approaches to tackling some of the most challenging cancer targets. Thank you for the invitation, Olivier Elemento, Regina Barzilay, and Sean Hanlon! #CancerMoonshot
Join us at The Colorado Convention Center for #ACSFall2024 where 3 of the Harmonic Discovery team members will be presenting. On Sunday, August 18, 2024, at 10:15, Navriti Sahni, PhD will give her presentation, Cmp-CGM: Chemotype Annotation, Screening, and Discovery of Compounds through a Coarse Grain Model based on Reduced Graph Representations, at Bluebird Ballroom 2H. On Tuesday, August 20, 2024, both Ryan Theisen, PhD, and Francesco Trozzi, PhD, will be presenting separately in Room 705. Catch Ryan’s presentation, Unveiling the Core Components of Success in Drug-target Interaction Modeling: A Systematic Study, at 8:20 AM, and Francesco’s presentation, Steering Colabfold Kinase Structures Generation to Discover Novel State-Specific Inhibitors Across the Kinome, at 11:00 AM. We hope to see you there!
We are thrilled to share that Harmonic Discovery was selected as the winner for the inaugural JP Morgan Asset Management Life Sciences Innovation Summit in Abu Dhabi! We would like to thank J.P. Morgan Asset Management Life Science Private Capital, Blue Horizon Advisors, Lyfebulb, the Department of Health Abu Dhabi, and the judges for hosting and organizing the summit. It was an honor to present Harmonic Discovery and our technology, and we are excited to develop novel therapeutics and support the life science ecosystem in the Emirati region. https://lnkd.in/e6hsjQd3
We're throwing a panel discussion with networking on Leveraging Gen AI for Drug Discovery on June 7th at 5pm. We are co-hosting with our friends over at Kaleidoscope.bio, Amazon Web Services (AWS), Gunderson Dettmer and a16z Tech Week at Biolabs@NYULangone for #Techweek NYC We have an awesome panel of speakers from biotech, industry and VC! Register here: https://lu.ma/tx1tr61x #TechWeek
Harmonic Discovery reposted this
Taking place on the sidelines of Abu Dhabi Global Healthcare Week (ADGHW), hosted by the Department of Health Abu Dhabi– Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, J.P. Morgan Asset Management’s Life Sciences Private Capital, Blue Horizon Advisors and United AlSaqer Group announce the 11 finalists of the inaugural Life Sciences Innovation Summit 2024 on May 14 – 15, 2024. Finalists selected to compete in the summit include: Algen Biotechnologies, Chun-Hao Huang, PhD, Co-Founder & CEO AnaCardio, Patrik Strömberg, PhD, CEO Chimera Therapeutics, Matthew Lorence, PhD, Co-Founder & CEO Harmonic Discovery, Rayees R., PhD, CEO Lactocore Group, Anton Malyshev, PhD, Founder & CEO Medicovestor, Inc., Seah Lim, PhD, CEO Oncoheroes Biosciences, Cesare Spadoni, PhD, Co-Founder & Chief Operating Officer Paradox Immunotherapeutics, Natalie J. Galant, PhD, PhD, Co-Founder & CEO SaudiVax, Mazen Hassanain MD, PhD, FACS, PhD, CEO Ypsilon Therapeutics, Dongxing Zha, PhD, Founder & CEO ZTI BIOSCIENCES, Jaden Hyungseok C., PhD, CEO Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are very pleased to be partnering with the stellar leadership of the Department of Health – Abu Dhabi, Blue Horizon Advisors, United AlSaqer Group, Cleveland Clinic Abu Dhabi and other local leaders in launching our inaugural innovation summit.” Nabil Kobeissi, Chief Executive Officer, Blue Horizon Advisors added: “We are grateful to these preeminent scientists and business leaders for coming to Abu Dhabi to experience our growing innovation hub and meet these stellar finalists. With over 150 highly qualified applications submitted from around the globe, clearly the medical research and innovation community is paying attention to this event.” The finalists will be judged by an esteemed panel, which includes: Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer Institute Jorge A. Guzman, MD, MBA, MD, CEO at Cleveland Clinic Abu Dhabi Prof. Shahrukh Khurshid Hashmi, Director of Research at Department of Health, Abu Dhabi David Hung, M.D., MD, Founder, President and CEO at Nuvation Bio Yasmine Hayek Kobeissi Ph.D, PhD, CQF, BSc., Executive Director at Blue Horizon Advisors Anya Schiess, Managing Partner at J.P. Morgan Life Sciences Private Capital Click Here: https://lnkd.in/dh6ESWYD #adghw #mededgemea #abudhabi #dohabudhabi #uae J.P. Morgan
Harmonic Discovery reposted this
We're thrilled to share that we will be pitching in Abu Dhabi for the JPM Life Sciences Innovation Summit. We're excited show how we can leverage our platform to solve precision pharmacology problems in rare diseases. Find out more below: https://lnkd.in/eXTVV-Rh
We're thrilled to share that we will be pitching in Abu Dhabi for the JPM Life Sciences Innovation Summit. We're excited show how we can leverage our platform to solve precision pharmacology problems in rare diseases. Find out more below: https://lnkd.in/eXTVV-Rh
We are thrilled to announce that that we are partnering with Turbine on a drug discovery program against the dark kinase NEK1. Utilizing Turbine's Simulated Cell Technology, NEK1 has been identified as playing a crucial therapeutic role in Head and Neck Carcinoma and Medulloblastoma. However, as a dark kinase, there are almost no known small molecule inhibitors of NEK1 available. We are excited to partner with Turbine, leveraging our Convergence platform, to discover and develop first-in-class NEK1 inhibitors! Learn more in our press release below. https://lnkd.in/eZbC67Vk
Harmonic Discovery reposted this
Licensing agreement with Harmonic Discovery and University of California, San Francisco to develop HD-10019, a novel drug targeting FLT3-mutated acute myeloid leukemia, marking a significant leap in AML treatment. #Innovation #Partnership #Licensing #Agreement https://lnkd.in/e-2yzJRf
We are thrilled to announce that we are in-licensing an asset developed by Professors Hong-Yu Li, PhD (previously of UAMS) and Neil Shah, MD PhD (UCSF) for FLT3 mutant AML! Learn more in our press release below! https://lnkd.in/exqKpQhF